Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Novartis’s Gilenya Given Final Approval by U.K.’s Cost Agency

Novartis AG’s multiple sclerosis pill Gilenya won final approval from England’s health-cost agency for some patients after the company agreed to a discounted price.

The National Institute for Health and Clinical Excellence, or NICE, recommended Gilenya as a treatment option for some adults with relapsing-remitting multiple sclerosis, a form of the disease in which symptoms worsen and improve periodically, it said in a statement today. The decision confirms a preliminary ruling made last month.

Gilenya costs about 19,196 pounds ($30,970). NICE isn’t disclosing the size of the discount that Novartis offered.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.